

Supplementary Table 2. Haplotype frequency

	Haplotype					Frequency (%)	
	<i>UGT1A9</i> *22 -118(T) ₁₀ /(T) ₉	<i>UGT1A7</i>	<i>UGT1A1</i> *60 -3279T/G	<i>UGT1A1</i> *28 -53(TA) ₆ >7	<i>UGT1A1</i> *6 211G/A	Total (n = 382)	Patients who received irinotecan- containing chemotherapy (n = 98)
I	10	TCGT(*1)	T	6	G	48.66	48.98
II	9	GAAC(*3)	T	6	A	17.35	16.84
III	9	GAAT(*2)	G	6	G	15.33	16.84
IV	10	TCGT(*1)	G	7	G	8.66	6.12
V	9	GAAT(*2)	G	7	G	1.98	2.55
VI	9	GAAC(*3)	G	7	G	1.77	4.08
VII	10	GAAC(*3)	T	6	A	1.76	1.53
VIII	9	GAAC(*3)	T	6	G	1.67	0.51
IX	10	TCGT(*1)	G	6	G	0.93	0.51
X	10	TCGT(*1)	T	6	A	0.52	0.00
XI	9	GAAT(*2)	T	6	A	0.39	0.00
XII	10	GAAC(*3)	G	7	G	0.29	1.02
XIII	10	GAAC(*3)	G	6	G	0.26	0.00
XIV	9	GAAT(*2)	T	6	G	0.26	0.51
XV	10	GAAT(*2)	G	6	G	0.17	0.51